MedImmune (part of AstraZeneca, UK) has entered into a research collaboration and licensing agreement with Immunocore focused on the development of novel cancer therapies using the latter's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. As per the agreement, the companies will co-operate in developing ImmTACs against selected cancer targets. AstraZeneca and MedImmune will retain the rights to develop and commercialise ImmTAC products further.

In its turn, Immunocore will receive a USD 20 million upfront payment per programme. It will also be eligible to receive up to USD 300 million worth of development and commercial milestone payments per target programme as well as tiered royalties.